Paper

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension

Published Sep 1, 1998 · L. Silver

American Journal of Ophthalmology

167

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCTLarge Human TrialHighly Cited

Study Snapshot

Brinzolamide 1.0% effectively reduces intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension, with less ocular discomfort compared to dorzolamide 2.0%.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension

References

Citations